Clinical Trials
322 trialsNAPISTAR1-01
Tubulis GmbH
RAINFOL-01
Genmab
EVEREST-2
A2 Biotherapeutics Inc.
PIKALO-1
Eli Lilly and Company
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
Jacobio Pharmaceuticals Co., Ltd.
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Terremoto Biosciences Inc.
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
AstraZeneca
A Phase Ib/â…¡ Clinical Trial of LBL-024 Combined With Paclitaxel in Patients With Platinum-resistant Ovarian Cancer
Nanjing Leads Biolabs Co.,Ltd
EB-DUALNK-OV
Beijing Biotech
ACTengine
Immatics US, Inc.
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
BioNTech SE
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Regeneron Pharmaceuticals
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Cancer Research UK
Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Children's Oncology Group
CERTIS1
AstraZeneca
MRD
Imunon
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Perspective Therapeutics
Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT
University of California, Irvine
Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors
Shenzhen Geno-Immune Medical Institute
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Revolution Medicines, Inc.
ANGELICA
Centre Leon Berard
MEDIOLA
AstraZeneca
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
Evopoint Biosciences Inc.
OCTOPOD
Theolytics Limited
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
GEN1047 for Solid Tumors - First in Human (FIH) Trial
Genmab
SELECT-2CAR
Beijing Biotech
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
National Institutes of Health Clinical Center (CC)
Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
CanariaBio Inc.
FRAPPE
Mayo Clinic
A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer
AstraZeneca
INX-315-01
Incyclix Bio
MAIA-ovarian
Compugen Ltd
ERADIC8
858 Therapeutics, Inc.
BetaBart
Radiopharm Theranostics, Ltd
Combination Therapy for Recurrent Ovarian Cancer
University of Louisville
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Artios Pharma Ltd
A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT
Case Comprehensive Cancer Center
DUAL-OV-CAR-NK
Beijing Biotech
ADVICE
Filamon LTD
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer
Sun Yat-sen University
PROOV
The Netherlands Cancer Institute
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
QLS5132 Combination Therapy in Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.